ID: ALA83053

Max Phase: Preclinical

Molecular Formula: C12H10N4O

Molecular Weight: 226.24

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Oc1[nH]cnc2c(Cc3cccnc3)cnc1-2

Standard InChI:  InChI=1S/C12H10N4O/c17-12-11-10(15-7-16-12)9(6-14-11)4-8-2-1-3-13-5-8/h1-3,5-7,17H,4H2,(H,15,16)

Standard InChI Key:  UYUIECWWPJVLGU-UHFFFAOYSA-N

Associated Targets(non-human)

Purine-nucleoside phosphorylase 70 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 226.24Molecular Weight (Monoisotopic): 226.0855AlogP: 1.60#Rotatable Bonds: 2
Polar Surface Area: 74.69Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 8.28CX Basic pKa: 5.38CX LogP: 1.06CX LogD: 1.01
Aromatic Rings: 1Heavy Atoms: 17QED Weighted: 0.70Np Likeness Score: -0.31

References

1. Niwas S, Chand P, Pathak VP, Montgomery JA..  (1994)  Structure-based design of inhibitors of purine nucleoside phosphorylase. 5. 9-Deazahypoxanthines.,  37  (15): [PMID:8057293] [10.1021/jm00041a027]

Source